# Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

> **NCT03847519** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advaxis, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell
- Metastatic Squamous Cell Carcinoma
- Metastatic Non-Squamous Cell Carcinoma

## Interventions

- **DRUG:** ADXS-503
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03847519
- **Lead sponsor:** Advaxis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03847519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03847519, "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03847519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*